MX380767B - Métodos para reducir el riesgo cardiovascular. - Google Patents
Métodos para reducir el riesgo cardiovascular.Info
- Publication number
- MX380767B MX380767B MX2016011975A MX2016011975A MX380767B MX 380767 B MX380767 B MX 380767B MX 2016011975 A MX2016011975 A MX 2016011975A MX 2016011975 A MX2016011975 A MX 2016011975A MX 380767 B MX380767 B MX 380767B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- cardiovascular risk
- present
- lipoproteins
- useful
- Prior art date
Links
- 230000002526 effect on cardiovascular system Effects 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 5
- 102000004895 Lipoproteins Human genes 0.000 abstract 3
- 108090001030 Lipoproteins Proteins 0.000 abstract 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 2
- 229940122392 PCSK9 inhibitor Drugs 0.000 abstract 2
- 230000000923 atherogenic effect Effects 0.000 abstract 2
- 231100000682 maximum tolerated dose Toxicity 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 229960004539 alirocumab Drugs 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461954094P | 2014-03-17 | 2014-03-17 | |
| US201462025400P | 2014-07-16 | 2014-07-16 | |
| US201462043182P | 2014-08-28 | 2014-08-28 | |
| EP15305293 | 2015-02-26 | ||
| PCT/US2015/020564 WO2015142668A1 (en) | 2014-03-17 | 2015-03-13 | Methods for reducing cardiovascular risk |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016011975A MX2016011975A (es) | 2016-12-05 |
| MX380767B true MX380767B (es) | 2025-03-12 |
Family
ID=52648962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016011975A MX380767B (es) | 2014-03-17 | 2015-03-13 | Métodos para reducir el riesgo cardiovascular. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20150284473A1 (enExample) |
| EP (2) | EP3119810B1 (enExample) |
| JP (3) | JP2017509624A (enExample) |
| KR (3) | KR20160132459A (enExample) |
| CN (3) | CN106794244A (enExample) |
| AU (3) | AU2015231713B2 (enExample) |
| CA (1) | CA2942549A1 (enExample) |
| EA (1) | EA039310B1 (enExample) |
| ES (1) | ES2978990T3 (enExample) |
| HU (1) | HUE066839T2 (enExample) |
| IL (1) | IL304491A (enExample) |
| MX (1) | MX380767B (enExample) |
| PL (1) | PL3119810T3 (enExample) |
| WO (1) | WO2015142668A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| KR102012111B1 (ko) | 2009-06-15 | 2019-08-19 | 아마린 파마, 인크. | 병용 스타틴 요법을 받는 대상체에서 ｌｄｌ－ｃ 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법 |
| PE20140372A1 (es) | 2011-01-28 | 2014-03-24 | Sanofi Sa | Composiciones farmaceuticas que comprenden anticuerpos humanos frente a pcsk9 |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| CN103930444B (zh) | 2011-09-16 | 2020-08-04 | 瑞泽恩制药公司 | 用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法 |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| JP2016523847A (ja) | 2013-06-07 | 2016-08-12 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｐｃｓｋ９のインヒビターの投与によりアテローム性動脈硬化を阻害する方法 |
| CN118105482A (zh) | 2013-11-12 | 2024-05-31 | 赛诺菲生物技术公司 | 用于与pcsk9抑制剂一起使用的给药方案 |
| EP3169710A1 (en) * | 2014-07-14 | 2017-05-24 | Amgen Inc. | Crystalline antibody formulations |
| WO2016011256A1 (en) | 2014-07-16 | 2016-01-21 | Sanofi Biotechnology | METHODS FOR TREATING PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (heFH) |
| JP6912374B2 (ja) * | 2014-07-16 | 2021-08-04 | サノフィ・バイオテクノロジー | 高コレステロール血症を有する高心血管リスク患者を処置するための方法 |
| WO2016046684A1 (en) | 2014-09-23 | 2016-03-31 | Pfizer Inc. | Treatment with anti-pcsk9 antibodies |
| WO2017031151A1 (en) | 2015-08-18 | 2017-02-23 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis |
| JOP20190112A1 (ar) * | 2016-11-14 | 2019-05-14 | Amgen Inc | علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي |
| US10329620B2 (en) * | 2017-01-12 | 2019-06-25 | Cardioforecast Ltd. | Methods and kits for treating cardiovascular disease |
| KR102401796B1 (ko) | 2017-04-13 | 2022-05-25 | 카딜라 핼쓰캐어 리미티드 | 신규의 펩타이드 기재 pcsk9 백신 |
| JP7426940B2 (ja) * | 2018-03-06 | 2024-02-02 | サノフィ・バイオテクノロジー | 心血管リスクを低減するためのｐｃｓｋ９阻害剤の使用 |
| WO2020010024A1 (en) * | 2018-07-02 | 2020-01-09 | Abcentra, Llc | Compositions and methods for reduction of lipoprotein a formation and treatment of aortic valve sclerosis and aortic stenosis |
| WO2020037153A1 (en) * | 2018-08-17 | 2020-02-20 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject |
| DK4056176T3 (da) | 2018-09-24 | 2024-05-06 | Amarin Pharmaceuticals Ie Ltd | Fremgangsmåde til at reducere risikoen af kardiovaskulære hændelser hos et individ |
| CN119060040A (zh) | 2019-01-18 | 2024-12-03 | 阿斯利康(瑞典)有限公司 | Pcsk9抑制剂及其使用方法 |
| EP4054625A4 (en) * | 2019-11-07 | 2026-01-07 | Medimmune Llc | Endothelial Lipase Antibodies for the Treatment of Cardiovascular Diseases |
| CN116350616A (zh) | 2019-11-12 | 2023-06-30 | 阿马里纳药物爱尔兰有限公司 | 降低心房纤颤和/或心房扑动受试者心血管事件风险的方法 |
| JP2023501745A (ja) * | 2019-11-18 | 2023-01-18 | エーディー ファーマシューティカルズ カンパニー，リミティド | 抗ｐｃｓｋ９抗体及びその使用 |
| KR20240012390A (ko) | 2021-04-21 | 2024-01-29 | 애머린 파마슈티칼스 아일랜드 리미티드 | 심부전의 위험을 감소시키는 방법 |
| CN114848849B (zh) * | 2022-04-25 | 2023-11-17 | 南方科技大学 | Pcsk9蛋白抑制剂在治疗心血管疾病中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| PE20140372A1 (es) * | 2011-01-28 | 2014-03-24 | Sanofi Sa | Composiciones farmaceuticas que comprenden anticuerpos humanos frente a pcsk9 |
| JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
-
2015
- 2015-03-13 HU HUE15712241A patent/HUE066839T2/hu unknown
- 2015-03-13 EP EP15712241.7A patent/EP3119810B1/en active Active
- 2015-03-13 KR KR1020167028383A patent/KR20160132459A/ko not_active Ceased
- 2015-03-13 PL PL15712241.7T patent/PL3119810T3/pl unknown
- 2015-03-13 CN CN201580024259.2A patent/CN106794244A/zh active Pending
- 2015-03-13 KR KR1020247040556A patent/KR20250006995A/ko active Pending
- 2015-03-13 US US14/657,192 patent/US20150284473A1/en not_active Abandoned
- 2015-03-13 KR KR1020227039740A patent/KR20220157516A/ko not_active Ceased
- 2015-03-13 ES ES15712241T patent/ES2978990T3/es active Active
- 2015-03-13 WO PCT/US2015/020564 patent/WO2015142668A1/en not_active Ceased
- 2015-03-13 CA CA2942549A patent/CA2942549A1/en active Pending
- 2015-03-13 JP JP2016556709A patent/JP2017509624A/ja active Pending
- 2015-03-13 EA EA201691847A patent/EA039310B1/ru unknown
- 2015-03-13 EP EP24160083.2A patent/EP4403213A3/en active Pending
- 2015-03-13 CN CN202210141133.5A patent/CN114558129A/zh active Pending
- 2015-03-13 MX MX2016011975A patent/MX380767B/es unknown
- 2015-03-13 AU AU2015231713A patent/AU2015231713B2/en active Active
- 2015-03-13 CN CN202210141115.7A patent/CN114642661A/zh active Pending
-
2021
- 2021-02-19 AU AU2021201118A patent/AU2021201118A1/en not_active Abandoned
- 2021-10-19 US US17/504,921 patent/US20220144969A1/en not_active Abandoned
-
2022
- 2022-07-22 JP JP2022116854A patent/JP2022141868A/ja active Pending
-
2023
- 2023-07-16 IL IL304491A patent/IL304491A/en unknown
-
2024
- 2024-07-19 JP JP2024115429A patent/JP2024147744A/ja active Pending
- 2024-07-31 AU AU2024205254A patent/AU2024205254A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP4403213A3 (en) | 2024-10-23 |
| AU2024205254A1 (en) | 2024-10-03 |
| JP2022141868A (ja) | 2022-09-29 |
| US20220144969A1 (en) | 2022-05-12 |
| EP4403213A2 (en) | 2024-07-24 |
| PL3119810T3 (pl) | 2024-07-15 |
| EP3119810A1 (en) | 2017-01-25 |
| EA201691847A1 (ru) | 2017-01-30 |
| CN114558129A (zh) | 2022-05-31 |
| CN114642661A (zh) | 2022-06-21 |
| CA2942549A1 (en) | 2015-09-24 |
| KR20220157516A (ko) | 2022-11-29 |
| MX2016011975A (es) | 2016-12-05 |
| AU2015231713A1 (en) | 2016-10-20 |
| EP3119810B1 (en) | 2024-02-28 |
| JP2017509624A (ja) | 2017-04-06 |
| HUE066839T2 (hu) | 2024-09-28 |
| JP2024147744A (ja) | 2024-10-16 |
| ES2978990T3 (es) | 2024-09-23 |
| AU2015231713B2 (en) | 2020-11-19 |
| KR20250006995A (ko) | 2025-01-13 |
| US20150284473A1 (en) | 2015-10-08 |
| EA039310B1 (ru) | 2022-01-12 |
| WO2015142668A1 (en) | 2015-09-24 |
| EP3119810C0 (en) | 2024-02-28 |
| CN106794244A (zh) | 2017-05-31 |
| IL304491A (en) | 2023-09-01 |
| KR20160132459A (ko) | 2016-11-18 |
| AU2021201118A1 (en) | 2021-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX380767B (es) | Métodos para reducir el riesgo cardiovascular. | |
| MX2020009246A (es) | Uso del inhibidor de pcsk9 para disminuir el riesgo cardiovascular. | |
| MX2017000627A (es) | Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe). | |
| MX2017000628A (es) | Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia. | |
| MX2016004580A (es) | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. | |
| EA201691320A1 (ru) | Способы лечения пациентов с гиперхолестеринемией, которая устойчива к терапии умеренными дозами статинов | |
| MX2019001481A (es) | Derivado de oxopicolinamida, metodo de preparacion y uso farmaceutico del mismo. | |
| MX2016000364A (es) | Metodos para tratar o prevenir afecciones oftalmologicas. | |
| BR112015023922A2 (pt) | composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes | |
| UY32989A (es) | Coposiciones terapéuticas concentradas de fosfolípidos | |
| MX2022010357A (es) | Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina. | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| MX2017011500A (es) | Combinaciones y formulaciones de dosis fijas que comprenden ácido 8-hidroxi-2,2,14,14- tetrametilpentadecanodioico (etc1002) y una o más estatinas y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. | |
| CR20220280A (es) | Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2 | |
| MX2017009122A (es) | Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol. | |
| BR112022018020A2 (pt) | Formas cristalinas de um composto farmacêutico | |
| MX2017013636A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas. | |
| CO2021005797A2 (es) | Métodos y formulaciones para tratar náuseas y vómitos inducidos por quimioterapia | |
| AR091724A1 (es) | Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica | |
| MX2017013643A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz. | |
| AR103636A1 (es) | Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol | |
| AR097179A1 (es) | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y flupirtina | |
| ZA202005282B (en) | Use of pcsk9 inhibitor for reducing cardiovascular risk | |
| AR097590A1 (es) | Métodos para tratar el síndrome del x frágil y trastornos relacionados | |
| BR112018072583A2 (pt) | composição farmacêutica de comprimido em comprimido estável |